Sign up to learn more about FILSUVEZ
This program is intended for US residents only.
Thank you for registering!
†NPI, National Provider Identifier.
Important Safety Information
Warnings & Precautions
Local hypersensitivity and skin reactions have been reported in patients treated with FILSUVEZ, including urticaria and dermatitis. If signs or symptoms of hypersensitivity occur, discontinue use immediately and initiate appropriate therapy.
Adverse Reactions
The most commonly reported adverse reaction in clinical trials was pruritus and pain at the wound application site (7.3%).
Patient Counseling Information
Please refer to Prescribing Information for administration instructions.
To report SUSPECTED ADVERSE REACTIONS, contact Chiesi USA Inc. at 1-888-661-9260 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
Please see Full Prescribing Information.
Indication
FILSUVEZ is indicated for the treatment of wounds associated with dystrophic and junctional epidermolysis bullosa (EB) in adult and pediatric patients 6 months of age and older.
Important Safety Information
Warnings & Precautions
Local hypersensitivity and skin reactions have been reported in patients treated with FILSUVEZ, including urticaria and dermatitis. If signs or symptoms of hypersensitivity occur, discontinue use immediately and initiate appropriate therapy.
Adverse Reactions
The most commonly reported adverse reaction in clinical trials was pruritus and pain at the wound application site (7.3%).
Patient Counseling Information
Please refer to Prescribing Information for administration instructions.
To report SUSPECTED ADVERSE REACTIONS, contact Chiesi USA Inc. at 1-888-661-9260 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
Please see Full Prescribing Information.
Indication
FILSUVEZ is indicated for the treatment of wounds associated with dystrophic and junctional epidermolysis bullosa (EB) in adult and pediatric patients 6 months of age and older.
PP-RA-01341 V1.0